Crinetics Pharmaceuticals, Inc. (CRNX)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CRNX Insider Trading Activity
CRNX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $23,932,355 | 33 | 100 |
Related Transactions
| Okey Stephanie | director | 0 | $0 | 1 | $811,650 | $-811,650 |
| Hassard James | Chief Commercial Officer | 0 | $0 | 2 | $1.33M | $-1.33M |
| Betz Stephen F. | Chief Scientific Officer | 0 | $0 | 10 | $1.42M | $-1.42M |
| Knight Jeff E. | Chief Operating Officer | 0 | $0 | 5 | $3.23M | $-3.23M |
| Pizzuti Dana | Chief Med and Dev Officer | 0 | $0 | 7 | $3.57M | $-3.57M |
| Wilson Marc | CFO | 0 | $0 | 4 | $5.08M | $-5.08M |
| Struthers Richard Scott | President & CEO | 0 | $0 | 4 | $8.49M | $-8.49M |
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Activity of Crinetics Pharmaceuticals, Inc.
Over the last 12 months, insiders at Crinetics Pharmaceuticals, Inc. have bought $0 and sold $23.93M worth of Crinetics Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Crinetics Pharmaceuticals, Inc. have bought $11.86M and sold $11.05M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $110,300 was made by Vivaldi Coelho Rogerio (director) on 2023‑06‑08.
List of Insider Buy and Sell Transactions, Crinetics Pharmaceuticals, Inc.
| 2025-03-19 | Sale | Struthers Richard Scott | President & CEO | 17,338 0.0184% | $34.20 | $593,017 | +0.63% | |
| 2025-03-19 | Sale | Betz Stephen F. | Chief Scientific Officer | 5,770 0.0061% | $34.20 | $197,353 | +0.63% | |
| 2025-03-19 | Sale | Knight Jeff E. | Chief Operating Officer | 7,162 0.0076% | $34.20 | $244,964 | +0.63% | |
| 2025-03-19 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 2,515 0.0027% | $34.20 | $86,021 | +0.63% | |
| 2025-02-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 5,000 0.0052% | $39.07 | $195,350 | -10.62% | |
| 2025-01-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 15,000 0.0158% | $52.09 | $781,350 | -32.62% | |
| 2024-12-02 | Sale | Struthers Richard Scott | President & CEO | 10,000 0.0108% | $57.57 | $575,700 | -32.60% | |
| 2024-11-22 | Sale | Knight Jeff E. | Chief Operating Officer | 501 0.0005% | $56.52 | $28,317 | -30.81% | |
| 2024-10-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 14,375 0.0194% | $54.63 | $785,306 | -1.91% | |
| 2024-09-26 | Sale | Wilson Marc | CFO | 25,000 0.0317% | $51.11 | $1.28M | +2.35% | |
| 2024-09-10 | Sale | Betz Stephen F. | Chief Scientific Officer | 1,035 0.0013% | $51.50 | $53,303 | +2.72% | |
| 2024-08-26 | Sale | Betz Stephen F. | Chief Scientific Officer | 3,000 0.0038% | $53.19 | $159,570 | -2.32% | |
| 2024-08-12 | Sale | Betz Stephen F. | Chief Scientific Officer | 3,000 0.0036% | $47.68 | $143,040 | +5.01% | |
| 2024-07-25 | Sale | Wilson Marc | CFO | 19,056 0.0244% | $53.88 | $1.03M | -2.57% | |
| 2024-07-25 | Sale | Betz Stephen F. | Chief Scientific Officer | 3,000 0.0038% | $53.43 | $160,290 | -2.57% | |
| 2024-07-15 | Sale | Wilson Marc | CFO | 25,000 0.0413% | $55.00 | $1.38M | -3.35% | |
| 2024-07-15 | Sale | Knight Jeff E. | Chief Operating Officer | 27,000 0.0446% | $55.00 | $1.49M | -3.35% | |
| 2024-07-10 | Sale | Betz Stephen F. | Chief Scientific Officer | 3,000 0.0044% | $48.55 | $145,650 | +3.41% | |
| 2024-07-05 | Sale | Hassard James | Chief Commercial Officer | 15,000 0.0199% | $44.08 | $661,200 | +19.38% | |
| 2024-07-03 | Sale | Pizzuti Dana | Chief Med and Dev Officer | 14,375 0.0194% | $44.87 | $645,006 | +18.19% |
Insider Historical Profitability
| Struthers Richard Scott | President & CEO | 329147 0.3537% | $11.33M | 2 | 15 | +35.75% |
| Wilson Marc | CFO | 111092 0.1194% | $3.82M | 0 | 8 | |
| Betz Stephen F. | Chief Scientific Officer | 108588 0.1167% | $3.74M | 0 | 48 | |
| Knight Jeff E. | Chief Operating Officer | 87491 0.094% | $3.01M | 0 | 6 | |
| Pizzuti Dana | Chief Med and Dev Officer | 72233 0.0776% | $2.49M | 0 | 11 | |
| Hassard James | Chief Commercial Officer | 29259 0.0314% | $1.01M | 0 | 2 | |
| Okey Stephanie | director | 6000 0.0064% | $206,520.00 | 0 | 1 | |
| EDELMAN JOSEPH | 5321032 5.7186% | $183.15M | 1 | 0 | <0.0001% | |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 5163517 5.5493% | $177.73M | 5 | 0 | +3.73% |
| Vivo Capital VIII, LLC | 10 percent owner | 298625 0.3209% | $10.28M | 1 | 13 | +10.46% |
| Madan Ajay | Chief Development Officer | 176995 0.1902% | $6.09M | 0 | 2 | |
| 5AM Ventures IV, L.P. | 94489 0.1015% | $3.25M | 1 | 3 | +10.46% | |
| Krasner Alan Seth | Chief Medical Officer | 43210 0.0464% | $1.49M | 1 | 2 | +10.46% |
| Fust Matthew K | director | 18536 0.0199% | $638,009.12 | 0 | 8 | |
| Vivaldi Coelho Rogerio | director | 5000 0.0054% | $172,100.00 | 1 | 0 | +51.5% |
Historical Insider Profitability vs. Competitors
$193,151,375 | 134 | 8.18% | $2.77B | |
$11,588,217 | 69 | 42.07% | $2.94B | |
$140,165,669 | 33 | 85.24% | $3.34B | |
$1,275,975,557 | 32 | 19.44% | $2.8B | |
$5,066,938 | 27 | 26.38% | $2.71B | |
$103,944,213 | 17 | 5.95% | $3.29B | |
$128,181,928 | 16 | 18.84% | $3.26B | |
$174,105,409 | 15 | 10.88% | $3.03B | |
$85,404,621 | 15 | 40.76% | $2.91B | |
$74,605,681 | 14 | 47.06% | $3.54B | |
$177,517,505 | 13 | 16.65% | $3.6B | |
$70,151,579 | 12 | 22.57% | $3.13B | |
Crinetics Pharmaceuticals, Inc. (CRNX) | $91,269,919 | 12 | 12.86% | $3.2B |
$35,908,794 | 10 | 126.31% | $3.23B | |
$1,711,150 | 9 | 31.59% | $3.25B | |
$4,623,072 | 7 | 11.07% | $3.62B | |
$36,900,000 | 3 | -9.12% | $3.71B | |
$103,599,972 | 2 | -36.81% | $2.64B | |
$95,000 | 1 | -0.78% | $2.62B |
CRNX Institutional Investors: Active Positions
| Increased Positions | 149 | +69.95% | 20M | +23.65% |
| Decreased Positions | 91 | -42.72% | 5M | -5.68% |
| New Positions | 37 | New | 936,336 | New |
| Sold Out Positions | 25 | Sold Out | 1M | Sold Out |
| Total Postitions | 271 | +27.23% | 100M | +17.97% |
CRNX Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $313,311.00 | 9.77% | 9.09M | +3M | +44.56% | 2024-12-31 |
| Fmr Llc | $307,751.00 | 9.6% | 8.93M | +4M | +100.37% | 2024-12-31 |
| Blackrock, Inc. | $259,049.00 | 8.08% | 7.52M | +965,251 | +14.74% | 2024-12-31 |
| Wellington Management Group Llp | $239,586.00 | 7.47% | 6.95M | +2M | +55.85% | 2024-12-31 |
| Driehaus Capital Management Llc | $211,681.00 | 6.6% | 6.14M | +255,766 | +4.35% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $186,638.00 | 5.82% | 5.41M | +469,748 | +9.5% | 2024-12-31 |
| Ecor1 Capital, Llc | $147,811.00 | 4.61% | 4.29M | 0 | 0% | 2024-12-31 |
| Farallon Capital Management Llc | $140,469.00 | 4.38% | 4.08M | +3M | +250.7% | 2024-12-31 |
| State Street Corp | $103,094.00 | 3.22% | 2.99M | +152,354 | +5.37% | 2024-12-31 |
| Janus Henderson Group Plc | $96,359.00 | 3.01% | 2.8M | +365,991 | +15.06% | 2024-12-31 |